[go: up one dir, main page]

WO1991008291A3 - Peptide associe a la latence et utilisations - Google Patents

Peptide associe a la latence et utilisations Download PDF

Info

Publication number
WO1991008291A3
WO1991008291A3 PCT/US1990/006292 US9006292W WO9108291A3 WO 1991008291 A3 WO1991008291 A3 WO 1991008291A3 US 9006292 W US9006292 W US 9006292W WO 9108291 A3 WO9108291 A3 WO 9108291A3
Authority
WO
WIPO (PCT)
Prior art keywords
latency associated
associated peptide
sequence
tgf
mature tgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/006292
Other languages
English (en)
Other versions
WO1991008291A2 (fr
Inventor
Arthur Levinson
Glenn R Hammonds
Anthony Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to EP90917236A priority Critical patent/EP0502036B1/fr
Priority to CA002068204A priority patent/CA2068204C/fr
Priority to DE69024369T priority patent/DE69024369T2/de
Publication of WO1991008291A2 publication Critical patent/WO1991008291A2/fr
Publication of WO1991008291A3 publication Critical patent/WO1991008291A3/fr
Anticipated expiration legal-status Critical
Priority to GR960400738T priority patent/GR3019343T3/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Une séquence d'acides nucléiques isolée comprend une séquence qui code un peptide associé à la latence ayant un poids moléculaire d'environ 75 000 lorsqu'on le mesure par SDS-PAGE de non réduction et peut être l'antagoniste d'une activité biologique de TGF-β mature, à condition que la séquence ne code pas également un TGF-β mature. Le peptide associé à la latence ainsi produit est utile en thérapie pour bloquer une activité délétère d'un TGF-β administré de manière exogène ou libéré de manière endogène, seul ou en combinaison avec un autre régulateur immun administré de manière exogène ou libéré de manière endogène. Il est également utile comme thérapie par cotraitement avec TGF-β mature, qui forme un complexe associé à la latence activable au niveau du site désiré in vivo.
PCT/US1990/006292 1989-11-22 1990-10-30 Peptide associe a la latence et utilisations Ceased WO1991008291A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP90917236A EP0502036B1 (fr) 1989-11-22 1990-10-30 Peptide associe a la latence et utilisations
CA002068204A CA2068204C (fr) 1989-11-22 1990-10-30 Peptides associes a la latence et leur utilisation
DE69024369T DE69024369T2 (de) 1989-11-22 1990-10-30 Latenz assoziierte peptide und deren verwendung
GR960400738T GR3019343T3 (en) 1989-11-22 1996-03-19 Latency associated peptide and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44168089A 1989-11-22 1989-11-22
US441,680 1989-11-22

Publications (2)

Publication Number Publication Date
WO1991008291A2 WO1991008291A2 (fr) 1991-06-13
WO1991008291A3 true WO1991008291A3 (fr) 1991-12-12

Family

ID=23753857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/006292 Ceased WO1991008291A2 (fr) 1989-11-22 1990-10-30 Peptide associe a la latence et utilisations

Country Status (10)

Country Link
EP (1) EP0502036B1 (fr)
JP (1) JPH05503003A (fr)
AT (1) ATE131872T1 (fr)
AU (1) AU639047B2 (fr)
CA (1) CA2068204C (fr)
DE (1) DE69024369T2 (fr)
DK (1) DK0502036T3 (fr)
ES (1) ES2083469T3 (fr)
GR (1) GR3019343T3 (fr)
WO (1) WO1991008291A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094550B2 (en) 1993-05-13 2006-08-22 Neorx Corporation Method to determine TGF-beta
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
US7625410B2 (en) 2001-05-02 2009-12-01 Boston Scientific Scimed, Inc. Stent device and method
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
US10611795B2 (en) 2013-11-15 2020-04-07 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
US11554117B2 (en) 2005-04-05 2023-01-17 Yale University Glutamate agents in the treatment of mental disorders

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU659412B2 (en) * 1990-06-25 1995-05-18 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
EP0690873B1 (fr) 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Facteur gde8 de differentiation de croissance
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
EP1382679A3 (fr) 1995-09-08 2004-11-10 Genentech, Inc. Antagonists du proteine apparentee a facteur de croissance endothelial vasculaire (VRP)
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
AU735200B2 (en) 1996-04-01 2001-07-05 Genentech Inc. APO-2LI and APO-3 apoptosis polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
ATE356212T1 (de) 1997-01-31 2007-03-15 Genentech Inc O-fukosyltransferase
US6100076A (en) * 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
GB9702943D0 (en) 1997-02-13 1997-04-02 Univ Manchester Wound healing
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1045906B1 (fr) 1998-01-15 2008-10-15 Genentech, Inc. Apo-2 ligand
US7141392B2 (en) 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
KR100844062B1 (ko) 2001-02-21 2008-07-07 미쓰이 가가쿠 가부시키가이샤 올레핀 중합용 촉매 및 이 촉매를 사용하는 올레핀중합체의 제조방법
NZ543755A (en) 2001-08-29 2008-04-30 Genentech Inc Bv8 nucleic acids and polypeptides with mitogenic activity
KR101118340B1 (ko) 2003-03-12 2012-04-12 제넨테크, 인크. 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의용도
WO2007050793A2 (fr) 2005-10-25 2007-05-03 The Johns Hopkins University Methodes et compositions de traitement du syndrome de marfan et de troubles associes
WO2007108992A2 (fr) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation de la thromboresistance endotheliale
EP3254696A1 (fr) 2006-10-03 2017-12-13 Genzyme Corporation Utilisation d'antagonistes de tgf-bêta pour traiter des nourrissons risquant de développer une dysplasie broncho-pulmonaire
US9089564B2 (en) 2007-03-22 2015-07-28 The Catholic University of Korea Industry-Academic Cooperatior Use of EC-SOD for treating angiogenesis-mediated eye diseases
US20120093796A1 (en) 2007-03-22 2012-04-19 Industry Academic Cooperation Foundation, The Catholic University Of Korea Novel use of ec-sod and method for preparing thereof
MX2011001900A (es) 2008-08-18 2011-08-17 Seoul Nat Univ Ind Foundation Metodo para controlar metastasis de cancer o migracion de celulas de cancer modulando el nivel celular de lisil-tarn sintetasa.
KR20130099255A (ko) 2008-09-15 2013-09-05 제넨테크, 인크. 세포 오스몰농도를 조절하기 위한 조성물 및 방법
KR101102485B1 (ko) 2008-10-10 2012-01-05 서울대학교산학협력단 Ｇｒｓ단백질 또는 이의 단편의 신규한 용도
PL2835053T3 (pl) 2010-03-12 2016-12-30 Terapia skojarzona do leczenia raka piersi
JP5886212B2 (ja) 2010-12-27 2016-03-16 Ｌｓｉｐファンド運営合同会社 ｉＰＳ細胞とその製造法
EP2737083A1 (fr) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Méthodes de diagnostic et de traitement du syndrome de myhre
WO2013062544A1 (fr) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cystéamine dans le traitement d'une maladie fibreuse
WO2013077534A1 (fr) 2011-11-23 2013-05-30 Cell Biotech Co., Ltd. Protéine p14 ayant une activité anti-cancéreuse et antiallergique et composition pharmaceutique comprenant celle-ci
WO2013100208A1 (fr) 2011-12-28 2013-07-04 京都府公立大学法人 Normalisation d'une culture de cellules endothéliales de la cornée
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US11382904B2 (en) 2013-10-31 2022-07-12 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
KR101619863B1 (ko) 2014-05-23 2016-05-24 주식회사 제노포커스 신규 베타-갈락토시다아제
KR101730035B1 (ko) 2015-03-20 2017-04-26 한국과학기술원 L-아스파르트산 유도체를 생산하는 변이미생물 및 이를 이용한 l-아스파르트산 유도체의 제조방법
KR101839595B1 (ko) 2015-04-13 2018-04-26 한국과학기술원 락탐의 제조방법
WO2016187312A1 (fr) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés et compositions pour traiter une infection par alphavirus
KR20160141123A (ko) 2015-05-28 2016-12-08 주식회사 제노포커스 고당전이 활성의 베타-갈락토시다제 변이체 및 그 용도
KR101702906B1 (ko) 2015-07-15 2017-02-22 주식회사 제노포커스 신규 알파-1,3-글루카나제
KR101756338B1 (ko) 2016-01-15 2017-07-10 고려대학교 산학협력단 L-시스테인 생산용 변이미생물 및 이를 이용한 l-시스테인의 제조방법
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2018026715A1 (fr) 2016-08-02 2018-02-08 Vaccinex, Inc. Procédés améliorés de production de bibliothèques de polynucléotides dans le virus de la vaccine/cellules eucaryotes
WO2018195338A1 (fr) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions et procédés pour le traitement d'inflammation pulmonaire
KR102658830B1 (ko) 2018-08-02 2024-04-19 에스케이이노베이션 주식회사 내열성 탄산무수화효소 변이체 및 이를 포함하는 이산화탄소 포집용 조성물
KR102346050B1 (ko) 2019-01-25 2022-01-03 주식회사 네오믹스 미백 활성을 갖는 신규 폴리펩타이드 및 이의 용도
US20240082387A1 (en) 2020-09-07 2024-03-14 Gi Cell, Inc. Fusion protein comprising coronavirus-derived receptor-binding domain and nucleocapsid protein, and use thereof
KR20220059399A (ko) 2020-11-02 2022-05-10 한국과학기술원 소수성 물질의 생산능이 향상된 재조합 미생물 및 이의 제조를 위한 세포막 엔지니어링 방법
KR102661294B1 (ko) 2020-12-24 2024-04-30 한국과학기술원 글루타르산 수송체 유전자가 도입된 재조합 미생물 및 이를 이용한 글루타르산의 제조방법
EP4624488A1 (fr) 2022-11-25 2025-10-01 Gil Medical Center Utilisation du gène variant-2 du transcrit fgf5 et d'une protéine de celui-ci pour prévenir, inhiber et traiter la fibrose hépatique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269408A2 (fr) * 1986-11-26 1988-06-01 Genentech, Inc. TGF-Bêta pour le traitement de maladies inflammatoires
EP0293785A2 (fr) * 1987-05-29 1988-12-07 Oncogen Limited Partnership Clonage et expression du facteur de croissance transformant simien SS-1
EP0356935A2 (fr) * 1988-08-25 1990-03-07 Oncogen Limited Partnership Inhibition de VIH utilisant le facteur de croissance transformant bêta
EP0376785A2 (fr) * 1988-12-16 1990-07-04 Oncogen Limited Partnership Clonage et expression du facteur de croissance transformant bêta 2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269408A2 (fr) * 1986-11-26 1988-06-01 Genentech, Inc. TGF-Bêta pour le traitement de maladies inflammatoires
EP0293785A2 (fr) * 1987-05-29 1988-12-07 Oncogen Limited Partnership Clonage et expression du facteur de croissance transformant simien SS-1
EP0356935A2 (fr) * 1988-08-25 1990-03-07 Oncogen Limited Partnership Inhibition de VIH utilisant le facteur de croissance transformant bêta
EP0376785A2 (fr) * 1988-12-16 1990-07-04 Oncogen Limited Partnership Clonage et expression du facteur de croissance transformant bêta 2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEBS Letters, vol. 242, no. 2, January 1989 Elsevier Science Publishers B.V. (Biomedical Division) F. Okada et al.: "One of two subunits of masking protein in latent TGF-beta is a part of pro-TGF-beta" pages 240-244 *
Science, vol. 247, 16 March 1990, A.M. Gray et al.: "Requirement for activin A and transforming growth factor-betal pro - regions in homodimer assembly", pages 1328-1330 *
The Journal of Biological Chemistry, vol. 263, no. 16, 5 June 1988, (US) L.M. Wakefield et al.: "Latent transforming growth factor-beta from human platelets", pages 7646-7654 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094550B2 (en) 1993-05-13 2006-08-22 Neorx Corporation Method to determine TGF-beta
US7625410B2 (en) 2001-05-02 2009-12-01 Boston Scientific Scimed, Inc. Stent device and method
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
US11554117B2 (en) 2005-04-05 2023-01-17 Yale University Glutamate agents in the treatment of mental disorders
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US10184106B2 (en) 2012-06-20 2019-01-22 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
US10611795B2 (en) 2013-11-15 2020-04-07 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents

Also Published As

Publication number Publication date
DE69024369T2 (de) 1996-06-13
ATE131872T1 (de) 1996-01-15
EP0502036B1 (fr) 1995-12-20
GR3019343T3 (en) 1996-06-30
CA2068204C (fr) 2002-02-12
WO1991008291A2 (fr) 1991-06-13
DK0502036T3 (da) 1996-05-06
CA2068204A1 (fr) 1991-05-23
DE69024369D1 (de) 1996-02-01
AU6744090A (en) 1991-06-26
JPH05503003A (ja) 1993-05-27
EP0502036A1 (fr) 1992-09-09
ES2083469T3 (es) 1996-04-16
AU639047B2 (en) 1993-07-15

Similar Documents

Publication Publication Date Title
WO1991008291A3 (fr) Peptide associe a la latence et utilisations
ZA943464B (en) Vascular endothelial growth factor 2
CA2006473A1 (fr) Traitement antiinfectieux ameliore
AU3035189A (en) Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents
AU649605B2 (en) Retinal, derivatives and their therapeutic use
ZA943465B (en) Transforming growth factor alpha H1
HK102192A (en) Human tumor necrosis factor and dna therefor
ES8101381A1 (es) Un procedimiento para la obtencion de un aglutinante para los tejidos a base de proteinas humanas o animales
AU4372389A (en) Portable adjustable child's chair
AU6808396A (en) Glial mitogenic factors, their preparation and use
GR3018401T3 (en) Polypeptides and polypeptide analogues with inhibitory activity against human elastase
CA2154080A1 (fr) Nouveau type d'activite anticoagulante a cofacteur
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
AU1384995A (en) Human circulating cytokine cc-1
GR3015890T3 (en) Novel peptides, their use as immuno suppressants and processes for their preparation.
AR244756A1 (es) Nuevos monomeros y polimeros coloreados, procedimiento de preparacion de dichos polimeros y procedimiento de separacion de sustancias biologicamente activas mediante el uso de dichos polimeros.
AR243237A1 (es) Un vector de expresion recombinante que contiene una secuencia de adn que codifica el factor neurotrofico ciliar humano,un microorganismo e.coli transformado,y linea celulares transformadas.
GR3017349T3 (en) Tert-butyloxycarbonyl-L-tyrosyl-peptidoglycan monomer and 125 I-labelled derivative thereof, their preparation and use.
CA2035443A1 (fr) Medicament analgesique et anti-inflammatoire
TW372873B (en) A novel anti-neoplastic cytokine
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
Nadler Valued moments of therapeutic movement and change distribution, rate of occurrence, sequences, and covariation.
WO1999015160A3 (fr) Utilisation de 2-aminotetralines 6,7-substituees pour la preparation de compositions pharmaceutiques pour le traitement de pathologies inflammatoires et/ou auto-immunes
Wilson Living with chemotherapy: Perceptions of husbands
GR3018675T3 (en) Antibodies to Promoters of colony stimulating factor activity.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2068204

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990917236

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990917236

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990917236

Country of ref document: EP